par Medios AG (isin : DE000A1MMCC8)
Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch
EQS-News: Medios AG / Key word(s): Personnel/Contract
Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch
31.05.2023 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Press release
Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch
Berlin, May 31, 2023 – The Supervisory Board of Medios AG ("Medios") has decided to extend the existing Executive Board contract of Falk Neukirch (Chief Financial Officer/CFO) ahead of schedule until April 30, 2026. Falk Neukirch has already been a member of the Executive Board since October 01, 2021 and is responsible for the Finance department.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG: "I am very pleased that we were able to extend the contract with Falk Neukirch as Chief Financial Officer. Since 2021, we have worked very trustfully and constructively with him as a proven financial expert. By appointing him for another three years, we strive for continuity and stability of the Management team and are best positioned to successfully implement our planned growth strategy."
Important events for Medios AG in the 2023 financial year:
June 16: Warburg Highlights – Hamburg
June 21: Ordinary Annual General Meeting 2023 – Berlin
August 14: Half-Year Financial Report as of 30 June 2023
September 20: Berenberg and Goldman Sachs 12th German Corporate Conference – Munich
November 14: Quarterly Statement as of 30 September 2023
November 17: Warburg "Meet the Future" – Berlin
About Medios AG
Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.
Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).
Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
c.nickolaus@medios.ag
www.medios.ag
Anna Höffken
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg
T +49 40 609 186 34
anna.hoeffken@kirchhoff.de
www.kirchhoff.de
Disclaimer
This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.
31.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: | English |
Company: | Medios AG |
Heidestraße 9 | |
10557 Berlin | |
Germany | |
Phone: | +49 30 232 566 - 800 |
Fax: | +49 30 232 566 - 801 |
E-mail: | ir@medios.ag |
Internet: | www.medios.ag |
ISIN: | DE000A1MMCC8 |
WKN: | A1MMCC |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1645605 |
End of News | EQS News Service |
1645605 31.05.2023 CET/CEST